| Literature DB >> 32123603 |
Ningning Zhao1,2, Shu Liu1, Junpeng Xing1, Zifeng Pi1, Fengrui Song1, Zhiqiang Liu1,2,3.
Abstract
Enrichment of trace bioactive constituents and metabolites from complex biological samples is challenging. This study presented a one-pot synthesis of magnetic polydopamine nanoparticles (Fe3O4@SiO2@PDA NPs) with multiple recognition sites for the magnetic dispersive solid-phase extraction (MDSPE) of ginsenosides from rat plasma treated with white ginseng. The extracted ginsenosides were characterized by combining an ultra-high-performance liquid chromatography coupled to a high-resolution mass spectrometry with supplemental UNIFI libraries. Response surface methodology was statistically used to optimize the extraction procedure of the ginsenosides. The reusability of Fe3O4@SiO2@PDA NPs was also examined and the results showed that the recovery rate exceeded 80% after recycling 6 times. Furthermore, the proposed method showed greater enrichment efficiency and could rapidly determine and characterize 23 ginsenoside prototypes and metabolites from plasma. In comparison, conventional methanol method can only detect 8 ginsenosides from the same plasma samples. The proposed approach can provide methodological reference for the trace determination and characterization of different bioactive ingredients and metabolites of traditional Chinese medicines and food.Entities:
Keywords: Enrichment; Fe3O4@SiO2@PDA NPs; Ginsenosides; Magnetic dispersive solid-phase extraction; Multiple recognition sites
Year: 2019 PMID: 32123603 PMCID: PMC7037655 DOI: 10.1016/j.jpha.2019.09.001
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
Scheme 1Schematic presentation of the proposed strategy for capture and characterization of ginsenosides by Fe3O4@SiO2@PDA NPs based on UPLC-MS method.
Fig. 1SEM images of Fe3O4, Fe3O4@SiO2, Fe3O4@SiO2@APTES and Fe3O4@SiO2@PDA NPs.
Fig. 2The EDX spectrum and element compositions of Fe3O4@SiO2@PDA NPs.
Fig. 3(A) X-Ray diffraction patterns of Fe3O4, Fe3O4@SiO2, Fe3O4@SiO2@APTES and Fe3O4@SiO2@PDA NPs. (B) FT-IR spectra of all the NPs. (C) VSM magnetization curves of all the NPs. (D) VSM magnetization curves of synthetic Fe3O4@SiO2@PDA NPs at different reaction times.
Fig. 4RSM response surface plots of the model for extraction of ginsenosides.
Calculated values of relative standard uncertainties, combined standard uncertainties and expanded uncertainties for the determination of 14 analytes in real plasma.
| Parameter | Analyte | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rg1 | Re | Rf | Rh1 | Rg2 | Rb1 | Rc | Rb2 | Rb3 | Rd | Rg3 | CK | PPD | Rh2 | |
| Concentration (mg/g) | 3.33 | 2.17 | 1.75 | 0.23 | 1.88 | 1.94 | 1.43 | 0.63 | 0.33 | 4.38 | 6.48 | – | – | – |
| LOD (mg/g) | 0.005 | 0.005 | 0.006 | 0.005 | 0.003 | 0.002 | 0.006 | 0.002 | 0.004 | 0.006 | 0.005 | 0.002 | 0.003 | 0.003 |
| LOQ (mg/g) | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
| Repeatability–RSD (%) | 2.89 | 7.15 | 4.73 | 0.83 | 2.03 | 2.26 | 2.89 | 1.74 | 2.17 | 5.80 | 2.38 | 2.11 | 9.99 | 2.52 |
| Trueness – recovery (%) | 95.30 ± 5.06 | 93.88 ± 7.12 | 88.80 ± 6.3 | 91.61 ± 10.06 | 98.94 ± 4.02 | 86.54 ± 3.22 | 85.30 ± 10.12 | 87.47 ± 6.1 | 86.22 ± 2.1 | 95.15 ± 10.5 | 91.27 ± 4.06 | 94.47 ± 12.2 | 93.77 ± 8.22 | 95.61 ± 15.78 |
| Uncertainty | ||||||||||||||
| Mass of sample – | 0.0099 | 0.0099 | 0.0099 | 0.0099 | 0.0099 | 0.0099 | 0.0099 | 0.0099 | 0.0099 | 0.0099 | 0.0099 | 0.0099 | 0.0099 | 0.0099 |
| Volume of sample – | 0.0087 | 0.0087 | 0.0087 | 0.0087 | 0.0087 | 0.0087 | 0.0087 | 0.0087 | 0.0087 | 0.0087 | 0.0087 | 0.0087 | 0.0087 | 0.0087 |
| Calibration – | 0.0004 | 0.0006 | 0.0042 | 0.0011 | 0.0378 | 0.0149 | 0.0107 | 0.0036 | 0.0037 | 0.0006 | 0.0042 | – | – | – |
| Recovery – | 0.027 | 0.038 | 0.035 | 0.055 | 0.020 | 0.019 | 0.059 | 0.035 | 0.012 | 0.055 | 0.027 | 0.065 | 0.044 | 0.083 |
| Repeatability – | 0.012 | 0.029 | 0.019 | 0.003 | 0.008 | 0.009 | 0.012 | 0.007 | 0.009 | 0.024 | 0.010 | 0.009 | 0.041 | 0.010 |
| LOD – | 0.0014 | 0.0022 | 0.0034 | 0.0230 | 0.0017 | 0.0012 | 0.0042 | 0.0029 | 0.0116 | 0.0013 | 0.0008 | – | – | – |
| Combined uncertainty | 3.2% | 5.0% | 4.2% | 6.1% | 4.5% | 2.9% | 6.3% | 3.8% | 2.3% | 6.1% | 3.3% | – | – | – |
| Expanded uncertainty (k = 2) | 6.5% | 9.9% | 8.5% | 12.2% | 9.1% | 5.8% | 12.5% | 7.7% | 4.7% | 12.3% | 6.5% | – | – | – |
| Result | ||||||||||||||
| Concentration ± U (mg/g) | 3.33 ± 0.22 | 2.17 ± 0.22 | 1.75 ± 0.15 | 0.23 ± 0.03 | 1.88 ± 0.17 | 1.94 ± 0.11 | 1.43 ± 0.18 | 0.63 ± 0.05 | 0.33 ± 0.02 | 4.38 ± 0.54 | 6.48 ± 0.42 | – | – | – |
Fig. 5The BPI chromatograms acquired by conventional methanol extraction method (A) and Fe3O4@SiO2@PDA NPs enrichment method (B).
Fig. 6The major fragmentation pathways of ginsenoside Re.
The major prototypes and metabolites of enrichment and identification using Fe3O4@SiO2@PDA NPs extraction method in the biological samples in the negative ion mode.
| NO. | RT (min) | Molecular formula | Neutral mass (Da) | Observed | Mass error | MS/MS (−) | Identified |
|---|---|---|---|---|---|---|---|
| 1 | 4.02 | C48H82O18 | 946.5501 | 991.5466 | −1.2 | 945.5379, 341.1087, 339.1293, 161.0456, 149.0452 | Gypenoside XDII |
| 2 | 4.04 | C42H72O14 | 800.4922 | 845.4857 | −5.0 | 799.4792, 637.4305, 619.4229, 475.3728, 391.2855, 179.0540, 161.0461 | Ginsenoside Rg1 |
| 3 | 4.05 | C48H82O18 | 946.5501 | 991.5466 | −1.2 | 945.5379, 783.4918, 765.4668, 637.4239, 619.4229, 475.3763, 457.3649, 391.2855, 179.0540, 161.0451 | Ginsenoside Re |
| 4 | 7.39 | C42H72O14 | 800.4922 | 845.4857 | −5.0 | 799.4792, 619.4229, 475.3824, 457.3679, 391.2855, 161.0461 | Ginsenoside Rf |
| 5 | 9.33 | C36H62O9 | 638.4394 | 683.4355 | −2.3 | 637.4387, 619.4215, 437.3419, 389.2689 | Ginsenoside Rh1(s) |
| 6 | 9.63 | C42H72O13 | 784.4973 | 829.4974 | 2.9 | 783.4918, 637.4305, 619.4229, 475.3824, 161.0461 | Ginsenoside Rg2 |
| 7 | 11.57 | C54H92O23 | 1108.6029 | 1153.5989 | −1.5 | 1107.5934, 945.5379, 783.4918, 621.4341, 459.3784, 323.0989, 179.0540 | Ginsenoside Rb1 |
| 8 | 13.05 | C53H90O22 | 1078.5924 | 1123.5879 | −2.0 | 1077.5831, 915.5270, 783.4917, 311.0969, 293.0834, 149.0437, 131.0334 | Ginsenoside Rc |
| 9 | 14.78 | C53H90O22 | 1078.5924 | 1123.5880 | −1.9 | 1077.5831, 915.5270, 783.4918, 311.0967, 293.0834, 149.0437, 131.0330 | Ginsenoside Rb2 |
| 10 | 15.16 | C53H90O22 | 1078.5924 | 1123.5877 | −2.1 | 1077.5831, 783.4918, 765.4789, 621.4341, 603.4291, 459.3878, 149.0435, 131.0331 | Ginsenoside Rb3 |
| 11 | 15.55 | C56H92O25 | 1164.5928 | 1163.5871 | 1.8 | 1119.5947, 1029.5271, 929.5473, 897.5217,781.4746,769.4740,753.4785 | Mal–Ginsenoside Rc |
| 12 | 15.79 | C56H92O25 | 1164.5928 | 1163.5873 | 1.9 | 1119.5951, 1059.5742, 1047.5737, 1029.5640, 927.5334, 835.4485, 783.4904, 765.4787 | Mal–Ginsenoside Rb2 |
| 13 | 16.31 | C48H82O18 | 946.5501 | 991.5446 | −3.2 | 945.5379, 783.4918, 621.4341, 459.38478, 179.0440, 161.0441 | Ginsenoside Rd |
| 14 | 16.62 | C36H62O10 | 654.4343 | 653.4253 | −1.8 | 493.3555, 477.3589, 391.2877 | Compound K+2O–2H2 |
| 15 | 17.12 | C42H72O13 | 784.4973 | 829.4969 | 2.3 | 783.4919, 621.4372, 537.3433, 475.3793, 375.2905, 159.0299 | Ginsenoside F2 |
| 16 | 18.02 | C36H60O11 | 668.4136 | 667.4039 | −2.9 | 387.2613, 305.1830, 303.1609, 297.2203 | Ginsenoside F1+2O–H2 |
| 17 | 18.37 | C42H72O13 | 784.4973 | 829.4969 | 2.3 | 783.4917, 621.4341, 537.3466, 459.3784, 161.0461 | Ginsenoside Rg3 |
| 18 | 18.62 | C36H60O11 | 668.4136 | 667.4074 | 2.4 | 489.2759, 463.3458, 457.3338, 407.2841, 391.2879 | Compound K+3O–H2 |
| 19 | 18.99 | C30H52O4 | 476.3866 | 475.3795 | 1.4 | 445.3646, 439.3549, 293.2081, 373.2738, 407.3216 | Protopanaxadiol + O |
| 20 | 19.51 | C30H52O5 | 492.3815 | 491.3749 | 2.4 | 473.3639, 387.3271, 361.2752, 347.2959, 245.1548 | Protopanaxadiol+2O |
| 21 | 20.25 | C30H52O5 | 492.3815 | 491.3752 | 3.1 | 475.3433, 443.3533, 441.3736, 403.3221, 401.3063 | Protopanaxadiol+2O |
| 22 | 22.25 | C30H50O5 | 490.3658 | 489.3589 | 1.8 | 437.3058, 423.3264, 393.3013, 371.2183, 343.2645, 331.2283, 305.2491 | Protopanaxadiol+2O–H2 |
| 23 | 22.81 | C30H50O5 | 490.3658 | 489.3593 | 2.7 | 475.3463, 427.3569, 387.2906, 375.2903, 373.2743, 361.2386, 343.2983, 331.2632 | Protopanaxadiol+2O–H2 |
Comparison of adsorption capability of pre-concentration methods for determination of ginsenosides.
| Pre-concentration method | Analytes | Techniques | Separation | Temperature | Capacity (mg/g) | LOQ (ng/mL) | Matrix | Reference |
|---|---|---|---|---|---|---|---|---|
| 70% aqueous methanol | Ginsenosides | UAE | Centrifugation | 7.48# | Panax ginseng | [ | ||
| Methanol | Ginsenosides | Refluxing | Centrifugation | 60–65 °C | 6.46# | American ginseng | [ | |
| Methanol | Ginsenosides | Refluxing | Centrifugation | 60–65 °C | 7.26# | Panax quin-quefolius | [ | |
| MeOH-ACN | Ginsenosides | Vortex | Centrifugation | 0.12–8.12 | Plasma | [ | ||
| Acetonitrile | Ginsenosides | Vortex | Centrifugation | 1–5 | Plasma | [ | ||
| Methanol | Ginsenosides | LLE | Centrifugation | 19.37* | 0.25–1 | Plasma | This work | |
| DES | Ginsenosides | LLE | Centrifugation | 36.65# | 0.4–40 | White ginseng | [ | |
| MIPs | Rg1 | SPE | Centrifugation | 27.74* | Total ginsenosides | [ | ||
| PDA-MMIPs | Anemoside B4 | MSPE | Magnetic separation | 5.65* | Feces | [ | ||
| PDA-MNPs | Ginsenosides | MDSPE | Magnetic separation | 28.32* | 0.25–1 | Total ginsenosides | This work | |
| 24.56* | 1–2 | Plasma |
UAE: Ultrasound-assisted extraction.
# mg of extracted ginsenosides from per g of white ginseng powder.
* mg of extracted ginsenosides from per g of adsorbent.